Yükleniyor... / Loading...
This observational study follows Canadian patients whose cancers carry rare molecular alterations, examining treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapies as well as patient-reported outcomes (PROs). It can enroll cancer patients aged 18 and older in whom a rare molecular alteration has been identified through molecular testing. It is a study without an assigned phase and is still recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Patients ≥ 18 years at cancer diagnosis * Diagnosed with malignant tumour(s) with molecular testing completed that identified rare molecular alterations * Accessible/available molecular testing reports/documentation to confirm type(s) of molecular alteration(s) (resulting from the conduct of polymerase chain reaction \[PCR\] based next generation sequencing \[NGS\], immunohistochemistry \[IHC\], fluorescence in situ hybridization \[FISH\], liquid biopsy) * Canadian resident received follow-up for cancer care in Canada or is currently receiving/planning follow-up for cancer care to occur in Canada at time of enrollment Exclusion Criteria: * Previous refusal of the deceased patient, when living, to enroll in this study or patient approached for this study is unable to provide informed consent